INTRODUCTION

Bone marrow transplant (BMT) is a treatment modality which brings about a chance of cure or a better prognosis for patients with malignant or benign blood diseases, such as thalassemia and sickle cell anemia, besides tumors such as renal cell carcinoma1,2.

Among BMT complications, the main one is the Graft Versus Host Disease (GVHD), which is an immune reaction resulting from the grafting of immunocompetent cells from a donor to an immunocompromised host. GVHD happens in between 50% and 80% of the patients submitted to BMT, and it is the main cause of long-term morbidity3.

Although the pathophysiology of GVHD is not fully unveiled, it is believed that it is primarily mediated by T-cells recognizing the tissues of the patient as antigens because of histocompatibility differences4.5.

GVHD affect more frequently the skin, liver, gastrointestinal tract and oral mucosa6. The oral manifestations of GVHD include lichenoid lesions, mucosa ulcerations, atrophic glossitis, diffuse erythema, taste disorders and salivary glands hypofunction causing xerostomia6-7.

Having said that, the present paper aims at reporting on a case diagnosed as GVHD, based on a biopsy of the oral mucosa, as well as discussing the relevant aspects of this pathology.

CASE PRESENTATION

Male, 15 year old, came to our dental clinic approximately 30 days after noticing whitish and diffuse lesions on his mouth. He reported he was not a smoker nor drank alcoholic beverages. The patient described having had severe aplastic anemia, and having been submitted to BMT approximately two years in the past.

Examining his mouth we noticed painless whitish lichenoid lesions on the mouth mucosa, palate and tongue (Figure 1). There were no suggestive lesions of such disorder on the skin nor in other organs, renal and liver functions were normal and he had a normal chest x-ray as well.

The onset of the lesions coincided with the suspension of cyclosporine - immunosuppressant, used to avoid de development of GVHD. Since the patient had been submitted to a BMT before and the clinical findings of a whitish lichenoid lesion matched descriptions of GVHD, we did a core biopsy of the tongue.

Histologically we could notice the presence of an oral mucosa fragment coated by hyperkeratinized squamous stratified epithelium, with areas of blurring on the basal layer. The underlying connective tissue was dense and fibrous, with intense inflammatory infiltrate, predominantly lymphocytic, located on the junction portion in a band shape (Figure 1). Therefore, by associating the previous clinical history with these histopathological findings we confirm the diagnosis of GVHD.

Cyclosporine was reinstated in a low dose, associated with rinsing the mouth with Betamethasone 0.1mg/ml, TID for 15 days, changing to once a day for an undetermined amount of time. The patient is being followed up, without recurrences.

DISCUSSION

GVHD can be limited, affecting only the oral mucosa or the skin, or it can be spread, affecting two or more organs6,7. The case hereby reported is the limited form of the GVHD, in which only the oral mucosa was affected, without any other clinical manifestation being observed.

The lichenoid lesions are the most commonly seen, and are distributed along the jugal, gingival and lingual mucosas. The differential diagnosis includes lichen planus, multiform erythema, lupus erythematosus and lesions associated with chemotherapy8-9.

The lesions seen in the oral mucosa of this patient had a lichenoid aspect, and we ruled out the possibility of the patient having an autoimmune disease - according to his interview, as well as having chemotherapy-related lesions because of the time interval between it and the lesions appearing - which was 2 years.

Therefore, considering his past of BMT and the histopathology findings, the conclusive diagnosis was of GVHD.

FINAL REMARKS

Because of the high incidence of oral mucosa involvement and the ease with which the biopsy can be made, such procedure can be used aiming at the definitive diagnosis of GVHD in post-BMT patients, thus contributing to a better prognosis and enhanced quality of life for these patients.

REFERENCES

1. Miklos DB, Kim HT, Miller KH. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood. 2005;105(7):2975-8.
2. Takahashi Y, Childs RW. Nonmyeloablative transplantation: an autologous-based immunotherapy for renal cell carcinoma. Clin Cancer Res. 2004;10:6358-9.
3. Michallet AS, Nicolini F, Furst S. Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT). Bone Marrow Transplant. 2005;35(6):601-8.
4. Buca A, Locatelli F, Vai S, Dell’Orco AM, Carugiuolo A, Falda M. Clinical grading of oral chronic graft-versus-host disease in 104 consecutive adult patients. Haematologica. 2005;90(4):567-9.
5. Imanguli MM, Pavletic SZ, Guadagnini JP, Brahim J, Atkinson JC. Chronic graft versus host disease of oral mucosa: Review of available therapies. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;101:1175-83.
6. Ratanathathorn V, Aiyash L, Lazarus HM, Fu J, Uberti JP. Chronic graft-versus-host disease: clinical manifestation and therapy. Mini review: Bone Marrow Transplant. 2001;28:121-9.

Keywords: biopsy, graft vs host disease, mouth mucosa.